BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25694611)

  • 1. Immunoprevention of chemical carcinogenesis through early recognition of oncogene mutations.
    Nasti TH; Rudemiller KJ; Cochran JB; Kim HK; Tsuruta Y; Fineberg NS; Athar M; Elmets CA; Timares L
    J Immunol; 2015 Mar; 194(6):2683-95. PubMed ID: 25694611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Both (+/-)syn- and (+/-)anti-7,12-dimethylbenz[a]anthracene-3,4-diol-1,2-epoxides initiate tumors in mouse skin that possess -CAA- to -CTA- mutations at Codon 61 of c-H-ras.
    Tang MS; Vulimiri SV; Viaje A; Chen JX; Bilolikar DS; Morris RJ; Harvey RG; Slaga TJ; DiGiovanni J
    Cancer Res; 2000 Oct; 60(20):5688-95. PubMed ID: 11059761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid induction of skin tumors in human but not mouse c-Ha-ras proto-oncogene transgenic mice by chemical carcinogenesis.
    Muto S; Katsuki M; Horie S
    Cancer Sci; 2006 Sep; 97(9):842-7. PubMed ID: 16805855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
    Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J
    Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
    Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene.
    Toes RE; Offringa R; Blom RJ; Brandt RM; van der Eb AJ; Melief CJ; Kast WM
    J Immunol; 1995 Apr; 154(7):3396-405. PubMed ID: 7534797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Activation of the Ha-ras oncogene in tumors induced in mice by transplacental exposure to 7,12-dimethylbenz(a)anthracene].
    Loktionov AS; Hollstein M; Martel N; Galendo D; Tomatis L; Yamasaki H
    Vopr Onkol; 1991; 37(3):297-303. PubMed ID: 1903226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties.
    Bristol JA; Schlom J; Abrams SI
    J Immunol; 1998 Mar; 160(5):2433-41. PubMed ID: 9498787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of p53 and ras gene mutations in DMBA-induced rat leukemias.
    Wei S; Kito K; Miyoshi A; Matsumoto S; Kauzi A; Aramoto T; Abe Y; Ueda N
    J Exp Clin Cancer Res; 2002 Sep; 21(3):389-96. PubMed ID: 12385583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic alterations cooperate with v-Ha-ras to accelerate multistage carcinogenesis in TG.AC transgenic mouse skin.
    Owens DM; Spalding JW; Tennant RW; Smart RC
    Cancer Res; 1995 Jul; 55(14):3171-8. PubMed ID: 7606738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonistic roles of CD4+ and CD8+ T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis.
    Yusuf N; Nasti TH; Katiyar SK; Jacobs MK; Seibert MD; Ginsburg AC; Timares L; Xu H; Elmets CA
    Cancer Res; 2008 May; 68(10):3924-30. PubMed ID: 18483278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
    Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
    Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
    Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant ras epitopes as targets for cancer vaccines.
    Abrams SI; Hand PH; Tsang KY; Schlom J
    Semin Oncol; 1996 Feb; 23(1):118-34. PubMed ID: 8607022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-type-specific ras mutations but no microsatellite instability in chemically induced mouse skin tumors and transformed 3T3 cells.
    Sasaki K; Bertrand O; Nakazawa H; Fitzgerald DJ; Mironov N; Yamasaki H
    Cancer Res; 1995 Aug; 55(16):3513-6. PubMed ID: 7627957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-specific activating mutations of Ha- and Ki-ras oncogenes in skin, lung, and liver tumors induced in mice following transplacental exposure to DMBA.
    Loktionov A; Hollstein M; Martel N; Galendo D; Cabral JR; Tomatis L; Yamasaki H
    Mol Carcinog; 1990; 3(3):134-40. PubMed ID: 1973614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of H-ras oncogenes in preneoplastic mouse mammary tissues.
    Kumar R; Medina D; Sukumar S
    Oncogene; 1990 Aug; 5(8):1271-7. PubMed ID: 2118247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of retrotransposition of long interspersed nucleotide element-1 in skin tumorigenesis induced by 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol-13-acetate.
    Okudaira N; Goto M; Yanobu-Takanashi R; Tamura M; An A; Abe Y; Kano S; Hagiwara S; Ishizaka Y; Okamura T
    Cancer Sci; 2011 Nov; 102(11):2000-6. PubMed ID: 21827582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgenic mice provide genetic evidence that transforming growth factor alpha promotes skin tumorigenesis via H-ras-dependent and H-ras-independent pathways.
    Jhappan C; Takayama H; Dickson RB; Merlino G
    Cell Growth Differ; 1994 Apr; 5(4):385-94. PubMed ID: 8043512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo Suppression of Heat Shock Protein (HSP)27 and HSP70 Accelerates DMBA-Induced Skin Carcinogenesis by Inducing Antigenic Unresponsiveness to the Initiating Carcinogenic Chemical.
    Yusuf N; Nasti TH; Ahmad I; Chowdhury S; Mohiuddin H; Xu H; Athar M; Timares L; Elmets CA
    J Immunol; 2015 May; 194(10):4796-803. PubMed ID: 25840912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.